Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Metabolite levels might help differentiate schizophrenia, bipolar

Publish date:: April 18, 2019

Key clinical point: Levels of metabolites could help clinicians deliver more targeted treatment earlier in patients’ disease course.

Major finding: Researchers assessing levels of metabolites such as phospholipids were able to identify patients as having schizophrenia or bipolar disorder, or as healthy controls, 87.1% of the time.

Study details: Study of 55 patients with schizophrenia or bipolar disorder and 30 healthy controls.

Disclosures: Dr. Joaquim reported no relevant disclosures.

Citation:

REPORTING FROM SIRS 2019

This Week's Must Reads

MDD: Modest improvements in female sexual functioning with adjunctive brexpiprazole,

Transcranial direct current stimulation not clinically relevant in MDD,

Interleukin-1 β and TNF-α hamper antidepressant response in MDD,

Impact of pimavanserin on anxious depression in patients with MDD,

Prior MDD moderates the association between endothelin-1 and post-ACS depressive symptoms,

Must Reads in Bipolar Disorder

Atopic dermatitis in adults, children linked to neuropsychiatric disorders,

Family-focused therapy linked to longer remissions in youth at risk for bipolar disorder,

Higher risk of bipolar disorder, depression, anxiety found with autism,

Increased Parkinson’s disease risk seen with bipolar disorder,

Virtual dark therapy tames manic episodes,